Dr Michael Lean (Chair of Human Nutrition [Medicine], University of Glasgow, Glasgow, UK) reviews the Diabetes Remission Clinical Trial (DiRECT). Weight loss is the most important thing patients can do to reduce glycated hemoglobin, reduce/eliminate comorbidities, and eventually gain diabetes remission. The DiRECT trial, funded by Diabetes UK, has been set up to help patients lose weight without bariatric surgery, and in turn become non-diabetic. Post-hoc analyses of the DiRECT trial have shown that almost 50% of patients can achieve remission of diabetes through weight loss, but the question remains, how do we identify these patients? Results showed there was no difference in males and females, older patients performed better than their younger counterparts, and certain medications hindered weight loss. Finally, Dr Lean highlights one of the main focuses of ADA 2018, which is drivers of disease progression, being high lipids and high insulin – both of which are caused by weight gain.
1. What was the background and rationale behind the Diabetes Remission Clinical Trial (DiRECT)? (0:14)
2. What were the findings of the post-hoc analysis presented at this meeting? (1:35)
3. What are the next steps in this area of research over the coming years? (3:08)
4. What are you highlights from this year’s ADA meeting? (4:15)
Filmed at the American Diabetes Association (ADA) Annual Meeting, June 2018
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!